

12 January 2024

ASX Announcement

Release of Securities from Escrow

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) advises in accordance with ASX Listing Rule 3.10A that the following securities will be released from escrow on or after their escrow expiry date of 28 January 2024.

Security Description	Number
Ordinary fully paid shares	62,732,537

Firebrick directors, Dr Stephen Goodall and Dr Peter Molloy each hold 30,054,412 (i.e. 60,108,824 shares in total) of the shares coming out of escrow. Neither has any intention of selling their shares in the Company.

This announcement was authorised for release by the Board of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company with the mission to develop and commercialise a povidone-iodine nasal spray. The Company has successfully developed a povidone-iodine nasal spray, called Nasodine® Nasal Spray and filed international trademarks and multiple patents on the product, including a formulation patent and two use patents, some of which have already been granted in the US, Europe and Australia. The Company has also completed six clinical trials for Nasodine, including a Phase 1 study, three Phase 2 studies and two Phase 3 studies, which have affirmed the product's safety and generally supported its efficacy as an antimicrobial nasal spray with utility in a range of clinical settings.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com